Drug Trial Radar · NCT07014137
A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 9, 2025
Primary completion
Mar 2, 2027
Study completion Mar 2, 2027
Sponsor
- Lead sponsor
- University Health Network, TorontoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ABSK043 is a new type of experimental drug that blocks a protein called programmed cell death ligand 1 (PD-L1), which is important in controlling the body's response to harmful substances including cancer cells. By blocking PD-L1 from working, ABSK043 may allow the body's immune system to recognize and kill cancer cells. ABSK043 is considered "experimental" because it has not been approved for sale by Health Canada. Health Canada has approved the study drug to be administered in this research study. The main purposes of this study are: * To see if patients with your type of cancer benefit from ABSK043. * To evaluate the safety and tolerability of ABSK043. * To identify biomarkers (Biological flags used to measure disease progress or drug effect.) in tumor tissues or blood that might help identify patients whose cancers respond to ABSK043, and which patients may develop side effects from these study drugs. Examples of biomarkers include the type of white blood cells in your tumor or proteins in your blood. It is anticipated that about 20 people will take part in this study from the Princess Margaret Cancer Centre.
Conditions
- Sarcoma
Interventions
ABSK043 single agentDrug
ABSK043 BID continuously for 28 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- overall response rate of ABSK043 therapy in angiogenic sarcomas (i.e. intimal, head/neck angiosarcoma, and EHE)Time frame: through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UHN- Princess Margaret Cancer Center
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.